Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of apraglutide in short bowel syndrome with intestinal failure
2020-005513-41Phase 3Active
- Sponsor
- VectivBio
- Start
- Mar 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of apraglutide in short bowel syndrome (SBS), sponsored by VectivBio. Primary endpoint: Adverse events (AEs). Started Mar 2021; status: active.
02
Drugs
apraglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2020-005513-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005513-41.